These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20019858)

  • 1. Use of palivizumab in children with congenital heart disease.
    Paediatr Child Health; 2003 Dec; 8(10):631-6. PubMed ID: 20019858
    [No Abstract]   [Full Text] [Related]  

  • 2. Palivizumab in congenital heart disease: should international guidelines be revised?
    Geskey JM; Thomas NJ; Brummel GL
    Expert Opin Biol Ther; 2007 Nov; 7(11):1615-20. PubMed ID: 17961086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.
    Bellavance M; Rohlicek CV; Bigras JL; Côté JM; Paquet M; Lebel MH; Mackie AS
    Paediatr Child Health; 2006 Jan; 11(1):19-23. PubMed ID: 19030237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
    Feltes TF; Sondheimer HM
    Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis.
    Claydon J; Popescu CR; Shaiba L; Christopherson C; Human D; Taylor R; Solimano A; Lavoie PM
    CMAJ Open; 2019; 7(1):E88-E93. PubMed ID: 30782771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
    Feltes TF; Cabalka AK; Meissner HC; Piazza FM; Carlin DA; Top FH; Connor EM; Sondheimer HM;
    J Pediatr; 2003 Oct; 143(4):532-40. PubMed ID: 14571236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.
    Chang RK; Chen AY
    Pediatr Cardiol; 2010 Jan; 31(1):90-5. PubMed ID: 19915892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.
    de Souza RP; Ribeiro ALR; de Menezes SAF; Machado LFA
    BMC Pediatr; 2019 Aug; 19(1):299. PubMed ID: 31462289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.
    Schmidt R; Majer I; García Román N; Rivas Basterra A; Grubb E; Medrano López C
    Health Econ Rev; 2017 Dec; 7(1):47. PubMed ID: 29260345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
    Ambrose CS; Chen X; Kumar VR
    Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Int; 2005 Aug; 47(4):397-403. PubMed ID: 16091076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
    Feltes TF; Sondheimer HM; Tulloh RM; Harris BS; Jensen KM; Losonsky GA; Griffin MP;
    Pediatr Res; 2011 Aug; 70(2):186-91. PubMed ID: 21522037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study.
    Ozyurt A; Narin N; Baykan A; Argun M; Pamukcu O; Zararsiz G; Sunkak S; Uzum K
    Pediatr Pulmonol; 2015 Oct; 50(10):1025-32. PubMed ID: 25156973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease.
    Walpert AS; Thomas ID; Lowe MC; Seckeler MD
    Congenit Heart Dis; 2018 May; 13(3):428-431. PubMed ID: 29436781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palivizumab compliance in congenital heart disease patients: factors related to compliance and altered lower respiratory tract infection viruses after palivizumab prophylaxis.
    Sel K; Aypar E; Dönmez YN; Aliyev E; Aykan HH; Karagöz T; Alehan D
    Cardiol Young; 2020 Jun; 30(6):818-821. PubMed ID: 32425145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities.
    Mohan AK; Braun MM; Ellenberg S; Hedje J; Coté TR
    Pediatr Infect Dis J; 2004 Apr; 23(4):342-5. PubMed ID: 15071290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015).
    Li A; Wang DY; Lanctôt KL; Mitchell I; Paes BA;
    Pediatr Infect Dis J; 2017 May; 36(5):445-450. PubMed ID: 28403044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC; Long SS;
    Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.